Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.
Labcorp Holdings Inc. (NYSE: LH) is frequently in the news as a global provider of innovative and comprehensive laboratory services. Company announcements highlight activities across diagnostics, oncology, neurology, consumer testing and biopharma laboratory services, giving investors and healthcare professionals insight into how Labcorp is evolving its business and scientific capabilities.
Recent press releases have covered topics such as quarterly financial results, updated full-year guidance and cash dividends on Labcorp’s common stock. These items show how the company communicates its financial performance, capital allocation decisions and participation in investor conferences and healthcare industry events.
Labcorp’s news flow also emphasizes developments in specialty testing. The company has reported on the expansion of its Plasma Detect molecular residual disease portfolio for monitoring recurrence risk in certain breast, lung and colon cancers, and on clinical studies featuring its MRD technology in journals such as Nature Medicine and Clinical Cancer Research. In neurology, Labcorp has announced plans to offer the Elecsys pTau181 blood test, cleared by the U.S. Food and Drug Administration to aid in the initial assessment for Alzheimer’s disease and other causes of cognitive decline.
Other news items describe collaborations and transactions, including agreements to acquire select outreach laboratory assets from health systems, the sale of select early development medical device testing assets to NAMSA, and partnerships that expand access to at-home testing through Labcorp OnDemand. Governance updates, such as board appointments and executive retirements, are also disclosed through company news.
This page aggregates these types of updates, allowing readers to follow Labcorp’s announcements on clinical testing innovations, oncology and neurology offerings, consumer-focused services, strategic partnerships, financial results and corporate governance.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.